Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

A Successfully Treated Case of Recurrent Focal Segmental Glomerulosclerosis (FSGS) with Plasmapheresis and High dose Methylprednisolone Pulse Therapy

  • Her, Sun Mi (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Lee, Keum Hwa (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Shin, Jae Il (Department of Pediatrics, Yonsei University College of Medicine)
  • Received : 2017.10.04
  • Accepted : 2017.10.07
  • Published : 2017.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Focal segmental glomerulosclerosis (FSGS) in children, which is a kind of nephrotic syndrome showing steroid resistance, usually progresses to a substantial number of end stage renal disease (ESRD). Although the pathogenesis of primary FSGS is unclear, several recent studies have reported that FSGS is associated with circulating immune factors such as soluble urokinase-type plasminogen activator receptor (suPAR) or anti-CD40 autoantibody. We report a successfully treated case of a 19-year-old female patient who experienced a recurrence of primary FSGS. After the diagnosis of FSGS, the patient progressed to ESRD and received a kidney transplantation (KT). Three days later, recurrence was suspected through proteinuria and hypoalbuminemia. She has been performed plasmapheresis and high dose methylprednisolone pulse therapy and shown remission status without increasing proteinuria for four years after KT. In conclusion, strong immunosuppressive therapy may be helpful for a good prognosis of recurrent FSGS, suppressing several immunologic circulating factors related disease pathogenesis.

Keywords

References

  1. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012;27:363-73. https://doi.org/10.1007/s00467-011-1939-1
  2. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 2011;365:2398-411. https://doi.org/10.1056/NEJMra1106556
  3. Niaudet P. [Lipoid nephrosis in childhood]. Rev Prat 2003;53:2027-32.
  4. Cochat P, Fargue S, Mestrallet G, Jungraithmayr T, Koch-Nogueira P, Ranchin B, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009;24:2097-108. https://doi.org/10.1007/s00467-009-1137-6
  5. Zimmerman SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 1984;22:32-8.
  6. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, et al. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med 2015;373:1916-25. https://doi.org/10.1056/NEJMoa1506362
  7. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5:2115-21. https://doi.org/10.2215/CJN.03800609
  8. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence af ter kidney transplantation. Sci Transl Med 2014;6:256ra136. https://doi.org/10.1126/scitranslmed.3008538
  9. Cochat P, Schell M, Ranchin B, Boueva A, Said MH. Management of recurrent nephrotic syndrome after kidney transplantation in children. Clin Nephrol 1996;46:17-20.
  10. Ehrich JH, Rizzoni G, Brunner FP, Brynger H, Geerlings W, Fassbinder W, et al. Combined report on regular dialysis and transplantation of children in Europe, 1989. Nephrol Dial Transplant 1991;6 Suppl 1:37-47.
  11. Baum MA. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 2004;8:329-33. https://doi.org/10.1111/j.1399-3046.2004.00181.x
  12. Reiser J, Nast CC, Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis 2014;21:417-21. https://doi.org/10.1053/j.ackd.2014.05.010
  13. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009;27:157-72. https://doi.org/10.1155/2009/504294
  14. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17:952-60. https://doi.org/10.1038/nm.2411
  15. Sever S, Trachtman H, Wei C, Reiser J. Is there clinical value in measuring suPAR levels in FSGS? Clin J Am Soc Nephrol 2013;8:1273-5. https://doi.org/10.2215/CJN.06170613
  16. Harita Y, Ishizuka K, Tanego A, Sugawara N, Chikamoto H, Akioka Y, et al. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol 2014;29:1553-60. https://doi.org/10.1007/s00467-014-2808-5
  17. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011;3:85ra46.
  18. Assmann KJ, van Son JP, Dijkman HB, Mentzel S, Wetzels JF. Antibody-induced albuminuria and accelerated focal glomerulosclerosis in the Thy-1.1 transgenic mouse. Kidney Int 2002;62:116-26. https://doi.org/10.1046/j.1523-1755.2002.00428.x
  19. Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007;20:102-5. https://doi.org/10.1111/j.1432-2277.2006.00395.x